Haemonetics Corporation $HAE Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group cut its stake in shares of Haemonetics Corporation (NYSE:HAE) by 7.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 892,354 shares of the medical instruments supplier’s stock after selling 72,830 shares during the period. Schroder Investment Management Group’s holdings in Haemonetics were worth $66,579,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Haemonetics by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after purchasing an additional 23,257 shares during the period. Royal Bank of Canada grew its position in Haemonetics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after buying an additional 24,650 shares during the last quarter. SG Capital Management LLC increased its stake in Haemonetics by 92.5% in the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after buying an additional 435,660 shares during the period. Citigroup Inc. raised its position in Haemonetics by 87.3% during the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock worth $39,755,000 after buying an additional 291,574 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Haemonetics by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock worth $35,336,000 after buying an additional 4,834 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HAE has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, November 25th. Raymond James Financial reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a report on Friday, November 14th. Mizuho dropped their target price on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Citigroup reduced their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Finally, Barrington Research lifted their price target on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.70.

Haemonetics Price Performance

HAE stock opened at $81.35 on Monday. The firm has a 50 day moving average of $58.57 and a 200-day moving average of $63.31. The company has a market cap of $3.81 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 0.91 and a beta of 0.43. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $88.86.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.Haemonetics’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period last year, the business posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.